MDxHealth SA re-affirmed earnings guidance for the year 2016. The company preliminary update on its year-end results, reporting that it expects to achieve its upgraded market guidance for full-year 2016 financial results following continued strong growth of ConfirmMDx® and early adoption of SelectMDx(TM) for Prostate Cancer during the year. The company previously upgraded its expected full-year revenue growth to more than 60% compared with its initial guidance predicting growth of 30-50% over 2015. Underlying earnings before interest, taxes, depreciation and amortization (EBIDTA) are also expected to improve compared to 2015. Full-year 2016 results will reflect initial sales of the Company's SelectMDx for Prostate Cancer 'liquid biopsy' test.